RBM-006

N/A

Report date: 2024/12/12 13:30:00

Base Information

Drug NameRBM-006
Drug Alias NameRBM-006
ClassificationBiologics
Mechanisms of ActionEctonucleotide pyrophosphatase/phosphodiesterase 2 inhibitors
TargetsEctonucleotide pyrophosphatase/phosphodiesterase 2
Therapy Area/IndicationsScleroderma, SystemicIdiopathic Pulmonary FibrosisLiver Cirrhosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRibomic
China Registration ClassN/A

Develop Information

Active CompaniesRibomic
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicIdiopathic Pulmonary FibrosisLiver Cirrhosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A